Depletion of protein S from plasma or inhibition of protein S in plasma by monoclonal antibodies induced a 5-t o 25-fold increase of prothrombin activation on the procoagulant endothelial cell matrix. A prolonged prothrombin activation was detected in protein S-depleted plasma up t o 20 minutes after onset of the thrombin generation. The increased prothrombin activation in protein S-depleted plasma could not be explained by the absence of the cofactor function of protein S for aPC because depletion of protein C from plasma did not result in increased prothrombin activation. These data provide further evidence for a strong anticoagulant function of protein S in plasma independent from activated protein C. 0 1995 by The American Society of Hematology.
Sepharose were purchased from Pharmacia (Uppsala, Sweden). Bovine serum albumin (BSA) and phorbol myristate acetate (PMA) were obtained from Sigma (St Louis, MO). Thermanox coverslips were from Flow Laboratories Inc (Woodcock Hill, UK). Other tissue culture supplies (media, antibiotics, and trypsin) were purchased from GIBCO Biocult (Paisley, UK). Purified recombinant tumor necrosis factor (TNF) (10' U/mg) was generously provided by Dr P. Lomedico (Hoffman La-Roche, Nutley, NJ). Polyclonal peroxidaseconjugated antibodies against protein S and protein C were obtained from Dakopatts (Glostrup, Denmark).
Monoclonal antibodies (MoAbs).
MoAbs were produced as described previouslyz7 and isolated from murine ascites fluid by protein G-Sepharose chromatography (Pharmacia) according to the instructions of the manufacturer.
Proteins. Human protein S was purified from plasma by immunochromatography using MoAb RU-PS7E9. This antibody, which recognizes both thrombin cleaved and intact protein S, was coupled to CNBr-sepharose (2 mg/mL gel) according to the instructions of the manufacturer. Plasma containing 0.2 mol/L NaCI, 0.1 m o m benzamidin, 40 pg/mL polybrene, 10 U/mL trasylol, 0.5 % Triton X-100, and 50 pglmL soybean trypsin inhibitor was passed over the 7EPcolumn. The column was washed with 0.4 m o m NaCI, 100 mmom benzamidin, and 50 mmol/L TRIS, pH 7.4. Bound proteins were eluted with 3 mom potassium isothiocyanate, 50 mmol/L TRIS, pH 7.4. Fractions containing protein S were pooled and dialyzed in 100 mrnovL NaCI, 30 mmom TRIS, pH 7.4. To remove C4b-binding protein the pool was applied to a Heparin-Sepharose 1816 VAN'T VEER ET AL column with a bedvolume of 3 mL that was equilibrated in buffer with 2 mmol/L CaCLZ. Before application, CaClz was added to the pool to a final concentration of 2 mmol/L. Flow-through fractions that contained protein S were made 5 mmol/L in EDTA and applied to a Q-Sepharose FF column with a bedvolume of 2 mL. After washing the column with TRIS-buffered saline, protein S was eluted with 0.5 mol/L NaCL 50 mmol/L TRIS. This protein S appeared as a single band of 70 kD on sodium dodecyl sulfate-polyacrylamide gel electrophoresis under nonreducing conditions. Approximately 25% of the protein S was cleaved in its thrombin sensitive region as was judged by the appearance of a 65-kD band under reduced conditions. Protein S was dialyzed against TBS and stored at -70°C. The specific activity of the preparation was 50 Ulmg.
FVIII-dejicient plasma. FVIII-deficient plasma was obtained from a severe hemophilia A patient with a FVIII level of greater than 1 .0%'.
Preparation of plasmu dejicient in protein S und protein C. A pool of fresh citrated plasma from six healthy individuals was immediately frozen in 10-mL vials using liquid nitrogen and then stored at -70°C. To remove remaining platelets and cell fragments, the plasma was filtered over a 0.22-pm filter (Millipore SA, Molsheim, France). Filtration of the plasma was necessary because the fragment of prothrombin, fragment,,, (F,+z), was already generated in unfiltered protein-deficient plasma after recalcification and anticoagulation with 20 UlmL low-molecular-weight heparin (LMWH) (Fragmin, Kabi Pharmacia). Control and protein C-deficient plasma was also filtered for the experiments in which protein S-depeleted plasma was used or when protein S was inhibited with antibodies. Protein S-deficient plasma from which cell fragments and platelets were removed remained at its baseline value of 0.7 nmol/L F,,?
during the time of a perfusion (25 minutes). Plasma was depleted of protein S or protein C by immunoadsorption at room temperature using MoAbs RU-PS7E9 (directed against EGF-like domains of protein S) or RU-PC4DI (directed against protein C), which were coupled to CNBr-activated Sepharose. Columns were equilibrated with 0.9% NaCL and plasma was applied to adsorp either protein S or C. Protein S and protein C antigen levels in the flow through plasma were determined with the use of an enzyme-linked immunosorbent assay. Capture antibodies and peroxidase-conjugated detection antibodies in these assays were specific rabbit polyclonal antibodies against protein S or protein C from Dakopatts. Protein S as well as protein C antigen levels were less than 1.0% in the Rowthrough fractions. The deficient fractions were pooled and used for the perfusion experiments. Control plasma was prepared by passing plasma over a control Sepharose column.
Endothelial cell culture urd mutrix isolution. Human umbilical vein endothelial cells (HUVECs) were isolated and cultured as described by Jaffe et al." in RPM1 1940 supplemented with 20% human serum, penicilin/streptomycin, and fungizone. At the second passage after isolation. HUVECs were trypsinized and seeded in culture medium on gelatin coated, 0.5% glutaraldehyde-fixed Thermanox coverslips of 2 X 6 cm and grown to confluency. The culture medium was refreshed a day before the cells were stimulated. Cells were stimulated for 4 hours with the indicated agents in culture medium, After stimulation of the cells, the tissue factor containing endothelial cell matrix was isolated by removing the cells with 0.1 mol\L NH,OH as described.'" Perfusion studies. To perform single pass perfusion studies over cellular surfaces, a rectangular Row chamber was designed based on the Row chamber of Sakariassen et al."' This Row chamber was previously used to study tissue factor-triggered prothrombinase activity under Row conditions." Coverslips of 2 X 6 cm covered with endothelial cell matrix were placed in the flow chamber on top of a 0.2-mm-high and S-mm-wide groove creating a surface of 3 cm' in contact with 60 pL of fluid. The flow chamber was placed in a water bath of 37°C and connected at the inlet to a syringe pump and at the outlet to a fraction collector via polyethylene tubes of 0.75-mm internal diameter. The Row profile in the reactor was determined with a laser-doppler technique"' and was found to be laminar throughout the flow area. The wall shear rate deduced from the parabolic Row profile was in agreement with the formula:
in which Q is the flow rate in microliters per second, h the slit height, W the slit width and y(w) the wall shear rate at a given Row rate."' After placing the coverslips in the flow chamber the matrix surface was first washed at a shear rate of 1 , OOO S -' (2 mL/min) for 10 minutes with 0.9% NaCI, 2.5 mmol/L CaCI,, 20 U/mL Fragmin (Kabi Pharmacia, Sweden) and 0.3% BSA. Before recalcification of the citrated plasma, it was anticoagulated by adding 20 UimL Fragmin. The plasma was recalcified to a free CaCl, concentration of 2.3 mmol/L by addition of I mol/L CaClz to a concentration of 17 mmolL. Plasma was perfused at a shear rate of IO0 S" and fractions were collected at the outlet into excess EDTA (final concentration 12.5 mmoVL) to prevent further activation of coagulation factors.
Detection of activation fragment F,+Z of prothrombin. Prothrombin activation was determined by estimation of the concentration of activation fragment F , + > of prothrombin in the collected fractions using the Enzygnost F,,, kit from Behring (Marburg, France) according to the instructions of the manufacturer.
RESULTS

Prothrombin activation
on endothelial cell matrix in plasma triggered by tissue ,factor under flow conditions. Plasma was perfused over the matrices of endothelial cells as described in Methods. Endothelial cells were stimulated For personal use only. on August 30, 2017. by guest www.bloodjournal.org From with varying concentrations of TNF or with 20 ngimL PMA (PMA-matrix) to induce increasing amounts of tissue factor in the matrix. When plasma was perfused over PMA matrix, prothrombin activation started after 5 minutes perfusion reaching an optimum of 135 nmol/L F1+, after 6 minutes perfusion (Fig 1) . A decline in levels from 110 to 20 nmol/L was observed between 9 and 12 minutes perfusion. Prothrombin activation was no longer detectable after 15 minutes perfusion. Perfusion of plasma over matrices of endothelial cells stimulated with 10, 100, or 600 pmol/L TNF resulted in a maximun level of prothrombin activation after 6 minutes perfusion of respectively 3,9, and 18 nmol/L Fl+,. Prothrombin activation declined after 6 minutes and in all perfusions prothrombin activation was no longer detectable after 15 minutes perfusion.
The effect of endogeneous protein S on prothrombin activation on endothelial cell matrix. To investigate the role of protein S as a coagulation inhibitor in a flow model we perfused plasma depleted of protein S over the tissue factor containing matrix of stimulated endothelial cells. Prothrombin activation on 10 pmol/L TNF matrices in protein Sdeficient plasma showed up as a peak of prothrombin activation after 9 minutes perfusion of 26 nmol/L F,,, followed by a decline in prothrombin activation to l 1 nmol/L F,,, at 15 minutes perfusion (Fig 2) . At 25 minutes perfusion, prothrombin activation was still detectable. Perfusion of control plasma over 10 pmoVL TNF matrices led to a F,,, level of 3 nmol/L after 9 minutes perfusion, whereas prothrombin activation was no longer detectable after 15 minutes. This means a 10-fold increase in prothrombin activation at 9 and 15 minutes perfusion on endothelial cell matrix in protein S-deficient plasma. A similar effect of depletion of protein S from plasma was observed on a 50 pmol/L TNF matrix, which is known to contain more tissue factor.32 A peak of 57 nmol/L F1+, was observed after 9 minutes perfusion. This peak declined from 25 to 7.5 nmol/L F,+, after 15 to 25 minutes of perfusion. Compared with the results obtained with perfusion of normal plasma over 50 pmol/L TNF matrix, this is a 5-to =25-fold increase in thrombin formation in protein S-deficient plasma at 9 and 15 minutes perfusion, respectively.
Reconstitution of purifed protein S to protein S-deficient plasma. To investigate whether the effects observed in plasma depleted of protein S by immunoadsorption were specific for protein S, we reconstituted the protein S level in protein S-deficient plasma with purified protein S and perfused this over 50 pmol/L TNF matrices (Fig 3) . Prothrombin activation in this reconstituted plasma was comparable with the levels observed in control plasma. This means that the increased prothrombin activation in protein S-deficient plasma in our system is not caused by the depletion of another protein from plasma than protein S. Immunoadsorption of plasma using antiprotein S antibodies also removes more than 50% of the C4b-binding protein via its interaction with protein S. Apparently this removal of C4BP does not affect prothrombin activation in our system.
Effect of addition of inhibitory antiprotein S MoAbs to plasma on prothrombin activation. Normal plasma was preincubated with a mixture of MoAbs directed against protein S. The mixture consisted of all the MoAbs characterized and described before,33 they were added to the plasma to a concentration of 450 nmom of each MoAb. Perfusion of this plasma over a 10 pmol/L TNF matrix resulted in a 10-to 25-fold increase in thrombin formation compared with the control situation (Fig 4) . The same effect of antiprotein S MoAbs was observed when plasma was perfused over 50 p m o K TNF matrices with slightly higher levels of F,,, compared with the 10 p m o K TNF matrices. The effect on prothrombin activation by antiprotein S MoAbs in plasma is similar to the effect of depletion of protein S from plasma by immunoadsorption. This confirms that the observed increase in prothrombin activation in plasma depleted from protein S by immunoadsorption is caused by the absence of protein S. Effect of protein C in plasma on prothrombin activation on endothelial cell matrix. Protein S is a cofactor of aPC in the inactivation of factor Va and factor VIIIa. To investigate whether depletion of protein S from plasma caused an increase in prothrombin activation on endothelial cell matrix (Figs 2, 3, and 4 ) because of the absence of protein S as a cofactor for protein C, we performed perfusions over endothelial cell matrix with protein C-depleted plasma. Perfusion of protein C-deficient plasma resulted in the same level of prothrombin activation on 10 pmol/L TNF matrix as observed in control plasma, whereas in the same experiment a 10-to 25-fold increase in prothrombin activation was observed in protein S-deficient plasma (Fig 5) . Prothrombin activation in protein C-deficient plasma perfused over a 50 pmoln TNF matrix was not increased compared with control plasma; it was even lower than in the the control situation. Whether this is a significant decrease is not yet clear.
Effect of FIXdFVIIIa complex on the role of protein S. To investigate whether prothrombin activation was dependent on the intrinsic Tenase complex (FIXaFVIIIa) and whether the effect of protein S on prothrombin activation was caused by an inhibitory effect on the tenase complex, perfusions were performed with FVIII-deficient plasma (Fig  6) . Protein S was inhibited with the same mixture of MoAbs For personal use only. on August 30, 2017. by guest www.bloodjournal.org From as used for the experiment described in Fig 4. From Figs 4 and 6, which were part of the same experiment using the same batch of matrices, it can be concluded that FVIII did not influence prothrombin activation on the endothelial cell matrix because prothrombin activation was identical in control and FVIII-deficient plasma. Inhibition of protein S resulted in a similar increase in prothrombin activation in FVIII-deficient plasma and control plasma. This indicates that protein S does not inhibit prothrombin activation by interference with the FIXa/FVIIIa complex in our system. Because prothrombin formation was not dependent on FVIII in our experimental setup, we cannot conclude that protein S has no effect on FIXalFVIIIa activity.
DISCUSSION
Protein S is known to function as a cofactor of aPC in the inactivation of factors Va and VIIIa.4"' Protein S is a protein with high affinity for phospholipids" that interacts with *C", FXa,24.2s and FVa.2'326 The thromboembolic complications in patients with decreased protein S levels emphasize the role of protein S as a natural anticoagulant. Here we describe an anticoagulant function of protein S independent of protein C. We investigated the anticoagulant role of protein S under flow conditions in plasma on a physiologic prothrombotic surface, the matrix of stimulated endothelial cells. Perfusions were performed with recalcified citrated plasma which was anticoagulated with LMWH according to Zwaginga et al.29 This type of anticoagulation allows tissue factor-dependent thrombin generation in plasma on a procoagulant surface. Plasma was perfused over endothelial cell matrices that were placed in a perfusion chamber. Prothrombin activation was detected in fractions collected at the outlet by measuring the generation of the F,,, fragment. Prothrombin has to be cleaved by FXa at positions Arg274-Thr275 and Arg323-Ile324 for the formation of fully active thrombin. Cleavage of prothrombin at position 274-275 results in the release of the F,+2 fragment of prothrombin and the formation of the intermediate prethrombin 2, which does not expose the active site of thrombin. Cleavage of prothrombin at position 323-324 leads to the formation of the intermediate meizothrombin, which exposes the active site but has a poor activity towards fibrinogen. Generation of the activation fragment F, + 2 certainly reflects prothrombinase activity, but it does not necessarily implicate the formation of active thrombin. Because in the presence of FVa the cleavage of the peptide bond at position 323-324 precedes the cleavage at position 274-27S,j4 the measurement of the generation of F,,, is probably a good estimation of thrombin formation in plasma. Furthermore, considerable F,+, generation resulted in a fibrin network on the endothelial cell matrices, indicating the formation of active thrombin in our experiments. Levels of prothrombin activation in control plasma were dependent on the amount of tissue factor deposited in the endothelial cell matrix (Fig 1 ) .
Prothrombin activation in protein S-depleted plasma was S-to 25-fold increased and prolonged compared with control plasma upon perfusion over matrices of stimulated endothelial cells. This increase in prothrombin activation in protein S-deficient plasma was abrogated by reconstitution with purified protein S. To further exclude the possibility that the observed effect is caused by the depletion of another protein from plasma by antiprotein S immunoadsorption, we performed perfusions with plasma in which protein S was inhibited by antiprotein S antibodies. This inhibition of protein S in plasma led to the same increase in prothrombin activation as observed in plasma depleted from protein S . The stimulatory effect on prothrombin activation by protein S depletion of plasma was also observed in the plasma of a hemophilia A patient, indicating that the observed effects on prothrombin activation of protein S are not caused by interference with the intrinsic pathway. However, prothrombin activation was independent on the presence of FVIII under the chosen conditions, so a potential effect of protein S on FIXaFVIIIa would not be observed. Protein S suppresses the protective effect of FXa on the inactivation of FVa by aPC?""' and functions as cofactor for the inactivation of FVa and VIIIa by aPC. Depletion of protein C from plasma did not result in an increased prothrombin activation indicating that the increased prothrombin activation observed in protein S-deficient plasma is not caused by the absence of the cofactor function of protein S for aPC. Although significant amounts of thrombin are formed on the endothelial cell matrix, this does not seem to result in significant protein C activation. This is probably because of the fact that endothelial cell matrix does not contain thrombomodulin, which is essential as cofactor for the activation of protein C by thrombin. Altogether this suggests that protein S itself is a potent inhibitor of thrombin formation on a physiologic procoagulant surface under flow conditions. Protein S is able to interact with factor XaZ4.2' and factor Va2s,26 and inhibits prothrombinase activity on cellular surfaces with a Ki of 100 to 200 nmolLZ5 Some evidence was already provided for an independent anticoagulant role of protein S in plasma.z6 The inhibition of prothrombinase activity by protein S may be explained either by a direct inhibition via interactions with FVa and FXa and/or interference with the binding of FXa, FVa, and prothrombin to phospholipids. Protein S interacts with high affinity to procoagulant phospholipids." The interaction of protein S with the phospholipid surface itself may interfere with the prothrombinase activity when the amount of phospholipid is limiting thrombin formation. Because all components of the prothrombinase complex assemble on the phospholipid surface, it is difficult to discriminate between the different possible functional interactions of protein S in regard to its inhibitory action on prothrombinase activity. Furthermore, if the interactions of protein S with FXa and FVa play an important role, these interactions may be enhanced by the binding of protein S, FXa, and FVa to the phospholipid surface, which results in an increase of the local concentration of the reactants on this surface. Thus, the study of protein S as prothrombinase inhibitor is complicated by the independent phospholipid binding of all components. To elucidate the working mechanism of protein S as an inhibitor of prothrombinase activity, it is necessary to study the FXa/FVa complex formation on a phospholipid surface as described'' in the presence of protein S. The protein C independent anticoagulant properties of protein S seem to become more important under flow conditions. Thrombin generation in plasma on In contrast with experiments with purified coagulation factors3'." a rapid decrease of prothrombinase activity was observed in plasma in our flow system (Fig  l) , and thrombin formation had ceased after 15 minutes. This was independent of the level of F,,, levels formed on matrices with different tissue factor activities. The dissociation constant (Kd) of the prothrombinase complex on a phospholipid surface lies in the subnanomolar range, and because of this, steady states of thrombin generation are observed when purified prothrombin is perfused over a limited amount of prothrombinase complexes bound to a phospholipid s~rface.~'.'' The observed increased and, moreover, prolonged prothrombinase activity in protein S-deficient plasma on endothelial cell matrices under flow conditions suggests that the anticoagulant action of protein S may be explained by dissociation of the prothrombinase complex in the presence of protein S. The observed anticoagulant action of protein S independent of protein C under flow conditions may further contribute to the understanding of the thrombotic complications caused by protein S deficiencies.
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